It is well-known that hydroxycarbamide (hydroxyurea), a cytoredutor drug indicated for MPN treatment, is capable of lowering serum inflammatory markers such as TNF-α, IL-6, CXCL8, and IL-1β in sickle cell disease patients (56, 57). This evidence concerns the gene IL6 and myeloproliferative disorder.